



Effects of CBD-Enriched *Cannabis sativa* Extract on Autism Spectrum Disorder Symptoms: An Observational Study of 18 Participants Undergoing Compassionate Use

Paulo Fleury-Teixeira¹, Fabio Viegas Caixeta², Leandro Cruz Ramires da Silva^{3,4}, Joaquim Pereira Brasil-Neto² and Renato Malcher-Lopes^{2*}

OPEN ACCESS

Edited by:

Mark Ware,
McGill University, Canada

Reviewed by:

Antonia Manduca,
Aix-Marseille Université, France
Rodrigo N. Romcy-Pereira,
Federal University of Rio Grande Do
Norte, Brazil
Radwa Khallil,
Jacobs University Bremen, Germany

*Correspondence:

Renato Malcher-Lopes
malcherlopes@gmail.com

Specialty section:

This article was submitted to
Neuropharmacology,
a section of the journal
Frontiers in Neurology

Received: 03 May 2018

Accepted: 14 October 2019

Published: 31 October 2019

Citation:

Fleury-Teixeira P, Caixeta FV, Ramires da Silva LC, Brasil-Neto JP and Malcher-Lopes R (2019) Effects of CBD-Enriched *Cannabis sativa* Extract on Autism Spectrum Disorder Symptoms: An Observational Study of 18 Participants Undergoing Compassionate Use. *Front. Neurol.* 10:1145. doi: 10.3389/fneur.2019.01145

¹ePrimeCare Healthcare SA, Belo Horizonte, Brazil, ²Department of Physiological Sciences, University of Brasília, Brasília, Brazil, ³Clinical Hospital, Federal University of Minas Gerais, Belo Horizonte, Brazil, ⁴Associação Brasileira de Pacientes de Cannabis Medicinal, Belo Horizonte, Brazil

Autism Spectrum Disorders comprise conditions that may affect cognitive development, motor skills, social interaction, communication, and behavior. This set of functional deficits often results in lack of independence for the diagnosed individuals, and severe distress for patients, families, and caregivers. There is a mounting body of evidence indicating the effectiveness of pure cannabidiol (CBD) and CBD-enriched *Cannabis sativa* extract (CE) for the treatment of autistic symptoms in refractory epilepsy patients. There is also increasing data support for the hypothesis that non-epileptic autism shares underlying etiological mechanisms with epilepsy. Here we report an observational study with a cohort of 18 autistic patients undergoing treatment with compassionate use of standardized CBD-enriched CE (with a CBD to THC ratio of 75/1). Among the 15 patients who adhered to the treatment (10 non-epileptic and five epileptic) only one patient showed lack of improvement in autistic symptoms. Due to adverse effects, three patients discontinued CE use before 1 month. After 6–9 months of treatment, most patients, including epileptic and non-epileptic, showed some level of improvement in more than one of the eight symptom categories evaluated: Attention Deficit/Hyperactivity Disorder; Behavioral Disorders; Motor Deficits; Autonomy Deficits; Communication and Social Interaction Deficits; Cognitive Deficits; Sleep Disorders and Seizures, with very infrequent and mild adverse effects. The strongest improvements were reported for Seizures, Attention Deficit/Hyperactivity Disorder, Sleep Disorders, and Communication and Social Interaction Deficits. This was especially true for the 10 non-epileptic patients, nine of which presented improvement equal to or above 30% in at least one of the eight categories, six presented improvement of 30% or more in at least two categories and four presented improvement equal to or above 30% in at least four symptom categories. Ten out of the 15 patients were using other medicines, and nine of these were

able to keep the improvements even after reducing or withdrawing other medications. The results reported here are very promising and indicate that CBD-enriched CE may ameliorate multiple ASD symptoms even in non-epileptic patients, with substantial increase in life quality for both ASD patients and caretakers.

Keywords: autism spectrum disorders, cannabidiol, epilepsy, *Cannabis sativa*, endocannabinoid system

INTRODUCTION

According to the DSM 5 (2013), Autism Spectrum Disorder (ASD) is characterized by functional deficits in three areas: mental development, social interaction, and behavior (1). In a multicenter epidemiological study done in 2012, involving nine countries, the median estimate of prevalence of ASD was 62/10.000 inhabitants (2). In clinical practice, the term ASD comprises a broad group of syndromes, diseases, and disorders (3, 4), that can affect cognitive development, motor skills, social interaction, communication, and behavior (frequently including auto and hetero-aggressiveness) (5–15). Often, this set of functional deficits results in incapacitation, lack of independence and severe distress for patients, families, and caregivers. For a recent review on this topic, refer to (16).

It is believed that ASD has multifactorial causes, generally associated with chromosomal or epigenetic changes in many different genes, which are often associated with neuronal function (17–24). Currently, there are no drugs or psychotherapeutic approaches capable of comprehensively improving life quality, social skills, and cognitive development of the most severe ASD patients (25–31). Currently available drugs may mitigate some specific symptoms, but generally speaking, they do so with a narrow range of effectiveness, and are often associated with important side effects (32, 33). Antipsychotic, antidepressant, or anxiolytic drugs, for example, may soothe autistic patients who display self-aggressive behavior (33–36). Antiepileptic drugs may be effective for seizure control and may even improve sleep quality and behavioral aspects (37). However, these drugs are known to cause major side effects (38–46). Moreover, none of these drugs has been shown to significantly improve the lack of social interaction and communication skills that characterize and impose great impact on the lives of patients with ASD and their families.

Recent observational studies and trials reporting the use of pure CBD or CBD-enriched cannabis extracts for the treatment of syndromes characterized by refractory epilepsy and regressive autism suggest therapeutic potential of cannabinoids for autistic symptoms (47–60). These studies, which include extracts with a CBD/THC ratio of up to 20/1, showed that, even in children and adolescents, the side effects of these extracts are infrequent and less damaging than those reported for drugs traditionally used either for ASD, ADHD, sleep disorders, or epilepsy.

Changes in the expression of peripheral cannabinoid receptors were verified in autistic patients, suggesting possible deficiencies

in the production and regulation of endogenous cannabinoids in ASD (61). This hypothesis has been recently confirmed specifically for anandamide, a major endocannabinoid, which is reduced in ASD patients (62). The understanding of the possible mechanisms involving the endocannabinoid system in the etiology of ASD has been derived from basic research in animal models. Special attention has been given to the neuronal hyperexcitability hypothesis and its possible relationship with the endocannabinoid system, which may also explain the higher incidence of epilepsy among ASD patients (63–68). Significant epileptiform EEG activity has been recorded even in the central nervous system of non-epileptic autistic children (69), which is consistent with the “intense world hypothesis,” that relates autistic symptoms to excessive neuronal activity and connectivity (70). Together, these findings strongly support the need for testing *Cannabis sativa* extracts (CEs) and isolated phytocannabinoids as pharmacological approaches to control severe symptoms in both epileptic and non-epileptic ASD patients (68). Furthermore, CBD has been shown to have anxiolytic (71–75) and antipsychotic effects (76–79) in humans. It is plausible to assume that such effects are, at least in part, mediated by CBD-induced accumulation of the endocannabinoid anandamide (80). Although the mechanisms underlying CBD-induced antiepileptic effects are not entirely clear, anandamide modulation is likely to play an important role (68). In this context, it is interesting to note that anandamide accumulation, caused by inhibitors of its metabolic degradation, leads to reduction of social interaction deficits in the valproate-treated animal model of autism (81).

Here we report an observational study analyzing the effects of the compassionate use of *Cannabis sativa* extract (CE) containing a 75/1 CBD/THC ratio, which was given to a group of 18 ASD patients. The participant group includes 11 patients with no history of epilepsy, two previously diagnosed with epilepsy but seizure-free for over a year, and 5 currently diagnosed with epilepsy who had seizures during the month preceding treatment with CE. Treatment results were assessed by means of monthly questionnaires and clinical evaluation. The results after 6–9 months of treatment were extremely promising for both epileptic and non-epileptic patients. For the latter, observed improvements were much more comprehensive with fewer adverse effects than it would have been expected from currently available therapies. These preliminary results indicate, therefore, the urgent need for more extensive and detailed clinical studies to further validate the use of ECs and cannabinoids for the treatment of severe ASD symptoms.

TABLE 1 | Cohort description and individual dosage* of phytocannabinoids prescribed.

Case #	Age (years)	Weight (kg)	CBD (mg/kg/day)	THC (mg/kg/day)	CBD (mg/day)	THC (mg/day)
01 ^f	07	25.0	4.00	0.05	100.00	1.33
02 ^m	12	45.0	3.89	0.05	175.00	2.33
03 ^m	09	33.0	3.79	0.05	125.00	1.67
04 ^m	12	80.0	4.38	0.06	350.00	4.67
05 ^f	11	34.0	5.88	0.08	200.00	2.67
06 ^m	10	26.0	3.85	0.05	100.00	1.33
07 ^m	09	32.0	3.91	0.05	125.00	1.67
08 ^f	08	35.0	4.29	0.06	150.00	2.00
09 ^m	14	49.0	4.08	0.05	200.00	2.67
10 ^m	12	32.0	4.69	0.06	150.00	2.00
11 ^m	18	89.5	3.35	0.04	300.00	4.00
12 ^m	07	15.5	6.45	0.09	100.00	1.33
13 ^f	15	46.0	5.43	0.07	250.00	3.33
14 ^m	09	25.0	6.00	0.08	150.00	2.00
15 ^m	11	35.0	4.29	0.06	150.00	2.00
Average	10.9	40.1	4.6	0.06	175.0	2.33
STD	3.06	20.18	0.94	0.01	74.40	0.99

*The administration schedule was of two daily doses, one in the morning and one in the evening.

^fFemale patients.

^mMale patients.

MATERIALS AND METHODS

Participants

The initial cohort included 18 ASD patients (ICD 10 = F84), aged 06–17 years (average 10), including five (28%) females and 13 (72%) males. Treatment with CE was spontaneously pursued by the patient's parents, who obtained legal authorization from the National Sanitary Surveillance Agency of Brazil (ANVISA) for the compassionate use of CE with all clinical assistance and treatment follow-up supervised by one of the authors of this article (P. F). Out of the 18 patients who had initiated treatment with standardized CE, three abandoned the treatment in the first month. Among the 15 patients who remained in the study, 05 had a diagnosis of epilepsy and had had seizures in the month preceding CE treatment, while the remaining 10 had never been diagnosed with epilepsy or had not had any clinical seizures for more than 12 months before treatment with CE. Among the five epileptic patients, one was diagnosed with Dravet's syndrome, two had epilepsy associated with cerebral palsy, and two had refractory epilepsy of undetermined etiology. Non-epileptic cases were randomly numbered 1–10, while epileptic cases were randomly numbered from 11 to 15. Demographic data are detailed in **Table 1**, while the individual patient's symptom profiles are detailed in **Table 2**.

Treatment

In August 2016, all patients started receiving standardized CE, with the same composition and origin, manufactured by

CBDRx[®] (Colorado, USA). The standardized CE contained a proportion of ~75/1 CBD/THC and was administered orally in capsules containing 25 or 50 mg of CBD and ~0.34 or 0.68 mg of THC, respectively (according to data provided by the manufacturer).

From the 18 patients who started standardized CE treatment, 15 had never used any CE previously, while three had already used CEs for periods ranging from 5 to 24 months. The standardized CE doses were established individually by a titration process within a dose range based on CBD doses previously reported for use of CBD-enriched CEs for treatment of refractory epilepsy associated with regressive autism (53, 54, 57, 58, 60). Thus, the average initial dose of CBD was ~2.90 mg/kg/day, varying according to individual case severity at the beginning of treatment (minimum: 2.30 mg/kg/day and maximum: 3.60 mg/kg/day). Dosage adjustment was done intensively during the first 30 days and more sparsely over the following 150 days. The average dose of CBD administered from then until the end of the study was 4.55 mg/kg/day, with a minimum of 3.75 and a maximum of 6.45 mg/kg/day (**Table 1**). The average dose of THC in the same period was 0.06 mg/kg/day, with a minimum of 0.05 and a maximum of 0.09 mg/kg/day. Individual maintenance doses used by patients after the adjustment period are shown in **Table 1**, which does not include patients who abandoned the standardized CE treatment during the first month. The administration schedule was of two daily doses, one in the morning and one in the evening.

Cannabinoid Extract Acquisition

By means of a non-commercial collaboration between the *Brazilian Association of Medicinal Cannabis Patients* (also known as AMAME) and the manufacturer CBDRx[®], the standardized CE was donated by the company CBDRx LLC at no charge to the patients.

Data Acquisition

The patient's parents and/or caregiver received a standardized form by e-mail (**Supplementary Material**), which should be answered once before the beginning of the study (baseline), and monthly throughout the duration of the CE treatment. In these forms the parents/caregivers were asked to estimate the severity of each of the eight symptom categories evaluated (see **Supplementary Material**). They should inform a score between 0 and 100, in which 0 means the lowest level of performance (or the maximum level of deficit and impairment associated to the symptom), and 100 means maximum performance (or complete absence of deficit and impairment associated to that symptom). The data presented here correspond to the difference observed between baseline results and results reported in the final month of treatment.

To ensure that the parents/caregiver properly understood the meaning of each category and that they were using the numeric scores in a consistent way throughout the study, the forms also contained two accessory questions (see **Supplementary Material**). In the first of these accessory questions the caregivers were asked to freely describe, in their own words, what changes they had observed since the last month.

TABLE 2 | Caretakers' perception of improvement in each symptom category.

Case #	Months of CE treatment [#]	Perception of improvement of symptoms (%) [*]							
		ADHD	BD	MD	AD	CSID	CD	SD	SZ ^{**}
01 ^f	09	15	15	-	10	15	15	50	-
02 ^m	06	40	10	20	30	60	40	40	-
03 ^m	09	40	30	40	20	40	30	50	-
04 ^m	15	30	20	20	10	40	30	30	-
05 ^f	27	50	25	35	20	25	35	40	-
06 ^m	09	30	00	-	00	00	20	-	-
07 ^m	09	15	15	15	15	15	15	50	-
08 ^f	09	20	20	-	10	60	20	60	-
09 ^m	09	00	-10	20	00	00	20	-	-
10 ^m	09	30	25	20	10	30	15	-	-
11 ^m	09	85	85	10	25	30	50	60	100
12 ^m	09	50	00	55	00	40	10	25	≥50
13 ^f	09	20	20	00	00	00	00	20	≥50
14 ^m	39	35	40	20	15	25	30	85	≥50
15 ^m	09	00	00	00	00	00	00	10	100
n ^{##}		15	15	12	15	15	15	12	05
Median		30	20	20	10	25	20	40	NA

ADHD, Attention Deficit/Hyperactivity Disorder; BD, Behavioral Disorders; MD, Motor Deficits; AD, Autonomy Deficits; CSID, Communication and Social Interaction Deficits; CD, Cognitive Deficits; SD, Sleep Disorders; SZ, Seizures. ^ffemale patients. ^mmale patients. ^{*}Lack of improvement is computed as 00% and worsening of symptoms are recorded as negative values. [#]Total time of CE use, including before the onset of standardized CE. ^{##}Number of patients presenting each symptom. A dash (-) indicate lack of the symptom before treatment onset. NA, Not applicable. ^{**}Scores for seizures are: 00, for lack of improvement, <50%, for reduction of <50% in the occurrence of SZ, ≥50%, for reduction of more than 50% in the occurrence of SZ; or 100% for cases of complete cessation of SZ.

In the second accessory question parents/caregivers were asked to inform the degree of change in a 5-level Likert-like scale, for each group of symptoms, in relation to the previous month. The three different responses allowed the detection of inconsistencies. Every month the patient's physician (P. F.) checked the numeric evaluation for consistency, and whenever an inconsistency was observed the physician would contact the parent/caregiver, either in person or by phone, and ask them to consider adjusting the response.

Evaluation of the Results

Patients were followed by means of periodic clinical evaluations made by the physician in charge. A monthly questionnaire was used to record treatment effects based on the answers given by the parents. Monthly standardized forms were filled out and contained questions covering the following symptom categories (see **Supplementary Material** for a detailed description of each category):

1. Attention Deficit/Hyperactivity Disorder (ADHD);
2. Behavioral Disorders (BD);
3. Motor Deficits (MD);
4. Autonomy Deficits (AD);
5. Communication and Social Interaction Deficits (CSID);
6. Cognitive Deficits (CD);
7. Sleep Disorders (SD);
8. Seizures (SZ).

Parents answered the initial questionnaires in August 2016 to assess the presence or absence of these symptoms before

the onset of CE treatment. In the monthly questionnaires that followed for the next 9 months, until April 2017, the perceived percentage change for each symptom category was assessed. Clinical assessments and monthly records also included information regarding side effects and changes, maintenance, reduction, or withdrawal of neuropsychiatric drugs that were already in use (**Table 2**).

The descriptive statistics in **Figures 1A,B** were plotted in MATLAB 2017a using the default settings of the *boxplot* function from the "Statistics and Machine Learning Toolbox."

RESULTS

General Results

Three patients (one female and two males, or 17% out of the cohort of 18 patients) chose to suspend treatment before the end of the first month due to the occurrence of adverse effects. In two of these patients a worsening of symptoms may have been due to the concomitant and unsupervised attempt to remove or reduce the dosage of antipsychotics. The third patient may have suffered adverse effects of the interaction of the prescribed cannabinoids with two other psychiatric medications that were being used simultaneously. For the remaining 15 patients that adhered to the standardized CE treatment, the consolidated results recorded during the final month of treatment are presented in **Table 2** and graphically depicted in **Figure 1A**. Results for all non-epileptic patients are presented in **Figure 1B**. No differences were observed between genders, and for that reason results for both genders are shown together.




FIGURE 1 | Improvement of symptoms observed in the patients that underwent CE treatment for at least 6 months. Data was collected from the caretakers' monthly follow-up questionnaires. **(A)** Pooled data from all 15 patients in the following categories: attention deficit/hyperactivity disorder (ADHD, $n = 15$); behavioral disorders (BD, $n = 15$); motor deficits (MD, $n = 12$); autonomy deficits (AD, $n = 15$); communication and social interaction deficits (CSID, $n = 15$); cognitive deficits (CD, $n = 15$); sleep disorders (SD, $n = 12$); convulsive seizures (SZ, $n = 5$). **(B)** Subset including only the 10 non-epileptic patients that underwent CE treatment for at least 6 months. Attention deficit/hyperactivity disorder (ADHD, $n = 10$); behavioral disorders (BD, $n = 10$); motor deficits (MD, $n = 7$); autonomy deficits (AD, $n = 10$); communication and social interaction deficits (CSID, $n = 10$); cognitive deficits (CD, $n = 10$); sleep disorders (SD, $n = 7$). Red lines denote medians, blue boxes the interquartile range, black whiskers the minimum and maximum values. Note that all categories present improvements that range from modest to robust, in spite of a very short period of treatment with CE.

Overall, mostly positive outcomes were reported for the 15 patients that adhered to the standardized CE treatment (one case for 6 months and 14 cases for 9 months), especially regarding improvements in sleep disorders, seizures, and behavioral crisis. Also, signs of improvement were reported for motor development, communication and social interaction, and cognitive performance (**Table 2**). We highlight that 14 out of these 15 patients (93%) showed improvements equal to or above 30% in at least one symptom category. Most patients that adhered to the treatment had improvements in more than one symptom category: seven patients (47%) had improvements equal to or above 30% in four or more symptom categories; two patients (13%) presented improvements equal to or above 30% in two symptom categories, and five patients (33%) presented improvements equal to or above 30% in one symptom category. Only one patient, referred to as Case 9, who was receiving multiple neuropsychiatric medications throughout the study, presented overall maintenance or worsening of symptoms.

Results Grouped by Symptom Categories

Clinical assessment and records of patients' evolution, which were filled in monthly by the patients' guardians/caretakers, targeted the main symptom categories associated with autism. Possible side effects of CE administration and modifications in the dosage of other neuropsychiatric drugs that were prescribed were also evaluated and are presented in **Table 3**. From the 15 patients who adhered to the treatment with standardized EC, 15 had symptoms of ADHD; 15 of BD; 12 of MD; 15 of AD; 15 of CSID; 15 of CD; 12 of SD; and 5 of SZ. Also, as shown in **Table 3**, 10 of these patients were also concomitantly taking other prescribed neuropsychiatric medications (OM).

At least 60% of patients showed improvements of 20% or more in ADHD, MD, CSID, BD, SD, and SZ. From the 15

patients who presented BD, eight (53.3%) had improvements equal to or above 20% in this symptom category. In AD, only four (26.7%) had improvements equal to or above 20%. The most robust results were found for ADHD, SD, and SZ, with more than 80% of patients presenting improvements equal to or above 30%. The results were particularly impressive for the control of seizures in the five epileptic patients, with seizure reduction of 50% in three cases and 100% in the other two cases. It is also worth noting that CE treatment made it possible to achieve a decrease in the dosage or to discontinue other neuropsychiatric medications in eight out of 10 patients that were receiving OM (**Table 2**).

Untoward Effects

The following adverse effects were reported among the 15 patients who adhered to CE treatment: sleepiness, moderate irritability (three cases each); diarrhea, increased appetite, conjunctival hyperemia, and increased body temperature (one case each). All these side effects were mild and/or transient. Two patients presented nocturia, which in one case appeared concomitantly to an improvement in sleep quality.

As stated previously, three patients interrupted the treatment before the end of the first month of CE treatment due to adverse effects such as insomnia, irritability, increased heart rate, and worsening of psycho-behavioral crisis. Additionally, there was one patient (Case 2) who adhered to the treatment until the sixth month and, in spite of improvement in some respects, showed significant worsening in psycho-behavioral aspects. The patients who experienced relevant side effects were all receiving several drugs (Patient 1: Clomipramine + Pericyazine; Patient 2: Risperidone + Prometazine + Sodium Valproate; Patient 3: Risperidone + Prometazine), including at least one antipsychotic, and in two cases there was an abrupt cessation of the antipsychotic.

TABLE 3 | Neuropsychiatric drugs taken by each patient during the study.

Case #	OM in use before CE treatment	OM in use after CE treatment	Summary of changes in OM	CE side effects
01 ^f	None	None	No OM	None
02 ^m	Risperidone + Melatonin	None	Complete withdrawal	None
03 ^m	None (used oxcarbazepine before the study)	None	No OM	None
04 ^m	None	None	No OM	Nocturia and polyuria
05 ^f	None (used several OM before the study)	None	Complete withdrawal	None
06 ^m	None	None	No OM	Hyperaemia, sleepiness, and transient increase in core temperature
07 ^m	Promethazine + Risperidone	Risperidone	Partial withdrawal	Transient sleepiness
08 ^f	Melatonin + Risperidone	Risperidone	Partial withdrawal + dosage reduction	Slight increase in appetite
09 ^m	Oxcarbazepine + Risperidone + Levomepromazine	Oxcarbazepine + Risperidone + Levomepromazine	None	None
10 ^m	None	None	No OM	None
11 ^m	Carbamazepine + Risperidone	Risperidone	Partial withdrawal + dosage reduction	Transient diarrhea at treatment onset
12 ^m	Phenobarbital	Phenobarbital	Complete withdrawal	Nocturia
13 ^f	Lamotrigine + Topiramate	Lamotrigine + Topiramate	Dosage reduction	Sleepiness and mild irritation
14 ^m	Oxcarbazepine + Levetiracetam + Topiramate + Valproate semisodium + Risperidone	Topiramate + Risperidone	Partial withdrawal + dosage reduction	Transient sleepiness and mild irritation when waking up
15 ^m	Risperidone + Oxcarbazepine	Risperidone + Oxcarbazepine	Dosage reduction	None

OM, alterations in other prescribed medication after introduction of CE (unaltered: no changes in the use of other medication was made; reduction, reduced the dosage of one or more medication; partial withdrawal, stopped completely the use of one of the medications; withdrawal, stopped completely the use of all other medication with the exception of CE. ^ffemale patients; ^mmale patients.

DISCUSSION

Here we report an observational study, which collected information provided by the clinician and the patients' parents during treatment of autistic patients with a CBD-enriched CE containing a rate of ~75:1 CBD to THC. Treatment duration ranged from 6 to 9 months. The initial cohort included 18 patients aged between 7 and 18. Three participants suspended CE use in the first 30 days of treatment, while 15 continued the use of standardized CE for six (01 patient) or nine (14 patients) months. All patients received the equivalent to an average CBD dose of 4.6 mg/kg/day and an average THC dose of 0.06 mg/kg/day. The prescribed THC dose is considered to be substantially below its safety margin (54). On the other hand, even low doses of pure THC, ranging from 0.04 to 0.12 mg/kg/day, have been previously shown to cause spasticity reduction, increased interest and connection with the environment, increased demonstration of initiative, reduction of seizure frequency, and improvement in dystonia of children with severe epileptic syndromes (82).

Previous studies have shown reliable efficacy and safety of CE containing a 20:1 CBD to THC proportion for the treatment of syndromes characterized by refractory epilepsy and regressive autism (54). Our positive results obtained from five epileptic patients (Table 1 and Figure 1A) corroborate the existing data regarding the effectiveness of CBD-enriched CE in the control

of refractory seizures (47–60). Moreover, to the best of our knowledge, this is the first report of a marked improvement in autistic symptoms of non-epileptic patients with the use of CE (Figure 1B).

Not all patients benefited equally from the treatment. From the initial cohort of 18 patients, four patients reported negative results. All of these participants were receiving multiple drugs, including at least one antipsychotic, which suggests the occurrence of undesirable drug interactions. In one of these cases, we suspect that the worsening of symptoms may have been due to an abrupt and unsupervised withdrawal of an antipsychotic drug. These observations point to a potential risk of paradoxical effects when introducing CE in a drug combination that includes antipsychotic drugs. This underscores the need for extra vigilance and of a gradual increase in the dosage of EC in patients receiving many drugs, and also to evaluate with caution the possibility of either partial or complete withdrawal of previously prescribed drugs.

Among the 15 patients who adhered to treatment for at least 6 months, 10 were non-epileptic or had not experienced seizures for at least 1 year (Table 2 and Figure 1B). These patients showed positive effects in almost all evaluated categories, namely: ADHD, MD, AD, CSID, CD, and SD. Particularly among non-epileptic, nine (90%) presented improvement equal to or above 30% in at least one of these categories, six (60%) presented improvement of 30% or more in at least two categories, and four (40%) presented

improvement equal to or above 30% in at least four symptom categories (Table 2). Therefore, the present observational study corroborates the notion that the range of therapeutic benefits of CBD-enriched CE extends to several distinct autistic symptoms, even in non-epileptic patients.

We note that due to the fact that the behavior/symptoms were annotated by caregivers, results on behavior improvement contain a significant degree of subjectivity. We also note that the reported results are subjectively quantitative, and that the degree of improvement may be non-linear (so that 60% improvement does not necessarily mean twice as much improvement as 30%).

Conspicuous positive effects, in both epileptic and non-epileptic patients, were observed in ADHD, SD, and CSID categories. It is evident that sleep quality improvement and hyperactivity reduction tend to have major positive impacts on mood and general health, as well as on the efficacy of psycho-pedagogic therapeutic interventions. Furthermore, in a long-term perspective, psycho-pedagogic therapy may potentiate the social, cognitive, and behavioral benefits observed after CE treatment. The least pronounced effects were seen on improvement of autonomy deficits (AD). This may indicate a need for a larger time interval to allow for consolidated routines and behavioral patterns, both from patients and from caretakers, to be remodeled before any benefit can be obtained from CE treatment.

The findings presented here, taken together, support the notion that many autism symptoms are associated to neuronal hyperexcitability, and indicate that CBD-enriched CE yields positive effects in multiple autistic symptoms, without causing the typical side effects found in medicated ASD patients. Most patients in this study had improved symptoms even after supervised weaning of other neuropsychiatric drugs. The intrinsic limitations of the present study, due to its observational nature, are the lack of control groups, the small cohort size, and potentially significant placebo effects (83). Further clinical trials are warranted to confirm these initial findings.

REFERENCES

1. American Psychiatry Association. *Diagnostic and Statistical Manual of Mental Disorders - DSM-5*, 5th ed. AP Association Editor, Belo Horizonte (2013).
2. Elsabbagh M, Divan G, Koh YJ, Kim YS, Kauchali S, Marcini C, et al. Global prevalence of autism and other pervasive developmental disorders. *Autism Res.* (2012) 5:160–79. doi: 10.1002/aur.239
3. Committee on Children With Disabilities. American academy of pediatrics: the pediatrician's role in the diagnosis and management of autistic spectrum disorder in children. *Pediatrics.* (2001) 107:1221–6. doi: 10.1542/peds.107.5.1221
4. Mahajan R, Bernal MP, Panzer R, Whitaker A, Roberts W, Handen B, et al. Clinical practice pathways for evaluation and medication choice for attention-deficit/hyperactivity disorder symptoms in autism spectrum disorders. *Pediatrics.* (2012) 130(Suppl 2S):125–38. doi: 10.1542/peds.2012-0900J
5. Kern JK, Geier DA, King PG, Sykes LK, Mehta JA, Geier MR. Shared brain connectivity issues, symptoms, and comorbidities in autism spectrum disorder, attention deficit/hyperactivity disorder, and tourette

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Ethics Committee on Human Research of the Health Sciences College of the University of Brasilia (Universidade de Brasília- UnB), under the protocol number CAAE 16308719.3.0000.0030. Written informed consent to participate in this study was provided by the participants' legal guardian/next of kin.

AUTHOR CONTRIBUTIONS

PF-T: concept, methods design, patient care, clinical supervision, writing contributions to the manuscript introduction, methods, and discussion. FC: data analysis, critical review of the manuscript, submission. LR: concept, methods design, writing contributions to the manuscript introduction. JB-N: critical review of the manuscript. RM-L: concept, methods design, scientific supervision, bibliographic review, writing contributions to the manuscript introduction, methods, and discussion.

FUNDING

FC was supported by FAP-DF (Grant 0193-001486/2017).

ACKNOWLEDGMENTS

We thank the Brazilian Association of Medical Cannabis Patients (Ama-Me) and Ama-Me's public affairs Director, Juliana Paolinelli, for introducing the patients to the authors. We thank Cassio Ismael and CBDRx for providing the cannabis extract to the patients from Ama-Me whose treatment is reported in this paper. We also thanks Carbisa for supporting our project.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fneur.2019.01145/full#supplementary-material>

6. Shuster J, Perry A, Bebko J, Toplak ME. Review of factor analytic studies examining symptoms of autism spectrum disorders. *J Autism Dev Disord.* (2014) 44:90–110. doi: 10.1007/s10803-013-1854-3
7. Hazen EP, Stornelli JL, O'Rourke JA, Koesterer K, McDougale CJ. Sensory symptoms in autism spectrum disorders. *Harv Rev Psychiatry.* (2014) 22:112–24. doi: 10.1097/01.HRP.0000445143.08773.58
8. Kral TV, Eriksen WT, Souders MC, Pinto-Martin JA. Eating behaviors, diet quality, and gastrointestinal symptoms in children with autism spectrum disorders: a brief review. *J Pediatr Nurs.* (2013) 28:548–56. doi: 10.1016/j.pedn.2013.01.008
9. Angelidou A, Alysandratos KD, Asadi S, Zhang B, Francis K, Vasiadi M, et al. Brief report: "allergic symptoms" in children with autism spectrum disorders. More than meets the eye? *J Autism Dev Disord.* (2011) 41:1579–85. doi: 10.1007/s10803-010-1171-z
10. Stoppelbein L, Sytsma-Jordan S, Greening L. Correlates of psychomotor symptoms in autism. *Int Rev Neurobiol.* (2005) 71:343–57. doi: 10.1016/S0074-7742(05)71014-X

11. Bozzi Y, Provenzano G, Casarosa S. Neurobiological bases of autism-epilepsy comorbidity: a focus on excitation/inhibition imbalance. *Eur J Neurosci.* (2018) 47:534–48. doi: 10.1111/ejn.13595
12. Cawthorpe D. Comprehensive description of comorbidity for autism spectrum disorder in a general population. *Perm J.* (2017) 21:16–088. doi: 10.7812/TPP/16-088
13. Pan PY, Yeh CB. The comorbidity of disruptive mood dysregulation disorder in autism spectrum disorder. *Psychiatry Res.* (2016) 241:108–09. doi: 10.1016/j.psychres.2016.05.001
14. Polyak A, Kubina RM, Girirajan S. Comorbidity of intellectual disability confounds ascertainment of autism: implications for genetic diagnosis. *Am J Med Genet B Neuropsychiatr Genet.* (2015) 168:600–8. doi: 10.1002/ajmg.b.32338
15. Stadnick N, Chlebowski C, Baker-Ericzen M, Dyson M, Garland A, Brookman-Frazee L. Psychiatric comorbidity in autism spectrum disorder: correspondence between mental health clinician report and structured parent interview. *Autism.* (2017) 21:841–51. doi: 10.1177/1362361316654083
16. Khalil R, Tindle R, Boraud T, Moustafa AA, Karim AA. Social decision making in autism: on the impact of mirror neurons, motor control, and imitative behaviors. *CNS Neurosci Ther.* (2018) 24:669–76. doi: 10.1111/cns.13001
17. Griffiths KK, Levy RJ. Evidence of mitochondrial dysfunction in autism: biochemical links, genetic-based associations, and non-energy-related mechanisms. *Oxid Med Cell Longev.* (2017) 2017:4314025. doi: 10.1155/2017/4314025
18. Hu Y, Ehli EA, Boomsma DI. MicroRNAs as biomarkers for psychiatric disorders with a focus on autism spectrum disorder: current progress in genetic association studies, expression profiling, and translational research. *Autism Res.* (2017) 10:1184–203. doi: 10.1002/aur.1789
19. Schroeder JC, Reim D, Boeckers TM, Schmeisser MJ. Genetic animal models for autism spectrum disorder. *Curr Top Behav Neurosci.* (2017) 30:311–24. doi: 10.1007/7854_2015_407
20. Todd RD. Genetic advances in autism hinge on the method of measuring symptoms. *Curr Psychiatry Rep.* (2005) 7:133–7. doi: 10.1007/s11920-005-0010-y
21. Tordjman S, Cohen D, Coulon N, Anderson GM, Botbol M, Canitano R, et al. Reframing autism as a behavioral syndrome and not a specific mental disorder: implications of genetic and phenotypic heterogeneity. *Neurosci Biobehav Rev.* (2017) 80:210. doi: 10.1016/j.neubiorev.2018.01.014
22. Ziats MN, Rennert OM. The evolving diagnostic and genetic landscapes of autism spectrum disorder. *Front Genet.* (2016) 7:65. doi: 10.3389/fgene.2016.00065
23. Trotter G, Srivastava L, Walker CD. Etiology of infantile autism: a review of recent advances in genetic and neurobiological research. *J Psychiatry Neurosci.* (1999) 24:103–15.
24. Walsh P, Elsabbagh M, Bolton P, Singh I. In search of biomarkers for autism: scientific, social and ethical challenges. *Nat Rev Neurosci.* (2011) 12:603–12. doi: 10.1038/nrn3113
25. Masi A, Lampit A, DeMayo MM, Glozier N, Hickie IB, Guastella AJ. A comprehensive systematic review and meta-analysis of pharmacological and dietary supplement interventions in paediatric autism: moderators of treatment response and recommendations for future research. *Psychol Med.* (2017) 47:1323–34. doi: 10.1017/S0033291716003457
26. Masi A, DeMayo MM, Glozier N, Guastella AJ. An overview of autism spectrum disorder, heterogeneity and treatment options. *Neurosci Bull.* (2017) 33:183–93. doi: 10.1007/s12264-017-0100-y
27. Lei J, Ventola P. Pivotal response treatment for autism spectrum disorder: current perspectives. *Neuropsychiatr Dis Treat.* (2017) 13:1613–26. doi: 10.2147/NDT.S120710
28. Eapen V, Nicholls L, Spagnol V, Mathew NE. Current status of biological treatment options in autism spectrum disorder. *Asian J Psychiatr.* (2017) 30:1–10. doi: 10.1016/j.ajp.2017.07.025
29. D'Agati D, Chang AD, Wachtel LE, Reti IM. Treatment of severe self-injurious behavior in autism spectrum disorder by neuromodulation. *J ECT.* (2017) 33:7–11. doi: 10.1097/YCT.0000000000000346
30. Cheng N, Rho JM, Masino SA. Metabolic dysfunction underlying autism spectrum disorder and potential treatment approaches. *Front Mol Neurosci.* (2017) 10:34. doi: 10.3389/fnmol.2017.00034
31. Bang M, Lee SH, Cho SH, Yu SA, Kim K, Lu HY, et al. Herbal medicine treatment for children with autism spectrum disorder: a systematic review. *Evid Based Complement Alternat Med.* (2017) 2017:8614680. doi: 10.1155/2017/8614680
32. Wink LK, Early M, Schaefer T, Pottenger A, Horn P, McDougle CJ, et al. Body mass index change in autism spectrum disorders: comparison of treatment with risperidone and aripiprazole. *J Child Adolesc Psychopharmacol.* (2014) 24:78–82. doi: 10.1089/cap.2013.0099
33. Fung LK, Mahajan R, Nozzolillo A, Bernal P, Krasner A, Jo B, et al. Pharmacologic treatment of severe irritability and problem behaviors in autism: a systematic review and meta-analysis. *Pediatrics.* (2016) 137(Suppl 2S):124–35. doi: 10.1542/peds.2015-2851K
34. Sahoo S, Padhy SK, Singla N, Singh A. Effectiveness of clozapine for the treatment of psychosis and disruptive behaviour in a child with atypical autism: a case report and a brief review of the evidence. *Asian J Psychiatr.* (2017) 29:194–5. doi: 10.1016/j.ajp.2017.07.012
35. Fitzpatrick SE, Srivorakiat L, Wink LK, Pedapati EV, Erickson CA. Aggression in autism spectrum disorder: presentation and treatment options. *Neuropsychiatr Dis Treat.* (2016) 12:1525–38. doi: 10.2147/NDT.S84585
36. Doyle CA, McDougle CJ. Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan. *Dialogues Clin Neurosci.* (2012) 14:263–79.
37. Hirota T, Veenstra-Vanderweele J, Hollander E, Kishi T. Antiepileptic medications in autism spectrum disorder: a systematic review and meta-analysis. *J Autism Dev Disord.* (2014) 44:948–57. doi: 10.1007/s10803-013-1952-2
38. Antel J, Hebebrand J. Weight-reducing side effects of the antiepileptic agents topiramate and zonisamide. In: Joost HG, editor, *Appetite Control. Handbook of Experimental Pharmacology, vol 209.* Berlin; Heidelberg: Springer. (2012) 433–66. doi: 10.1007/978-3-642-24716-3_20
39. Ijff DM, Aldenkamp AP. Cognitive side-effects of antiepileptic drugs in children. *Handb Clin Neurol.* (2013) 111:707–18. doi: 10.1016/B978-0-444-52891-9.00073-7
40. Dreifuss FE, Langer DH. Side effects of valproate. *Am J Med.* (1988) 84:34–41. doi: 10.1016/0002-9343(88)90055-1
41. Duggal HS. Psychotic symptoms associated with topiramate: cognitive side effects or worsening of psychosis? *J Clin Psychiatry.* (2004) 65:1145. doi: 10.4088/JCP.v65n0818c
42. Hesami O, Hosseini SS, Kazemi N, Hosseini-Zijoud SM, Moghaddam NB, Assarzagdegan F, et al. Evaluation of ocular side effects in the patients on topiramate therapy for control of migrainous headache. *J Clin Diagn Res.* (2016) 10:NC01–4. doi: 10.7860/JCDR/2016/16263.7339
43. Nicolai J, Smith SJ, Keunen RW. Simultaneous side effects of both clozapine and valproate. *Intensive Care Med.* (2001) 27:943. doi: 10.1007/s001340100937
44. Wood JR, Nelson-Degrave VL, Jansen E, McAllister JM, Mosselman S, Strauss JF 3rd. Valproate-induced alterations in human theca cell gene expression: clues to the association between valproate use and metabolic side effects. *Physiol Genomics.* (2005) 20:233–43. doi: 10.1152/physiolgenomics.00193.2004
45. Koliqi R, Polidori C, Islami H. Prevalence of side effects treatment with carbamazepine and other antiepileptics in patients with epilepsy. *Mater Sociomed.* (2015) 27:167–71. doi: 10.5455/msm.2015.27.167-171
46. Langbehn DR, Alexander B. Increased risk of side-effects in psychiatric patients treated with clozapine and carbamazepine: a reanalysis. *Pharmacopsychiatry.* (2000) 33:196.
47. Treat L, Chapman KE, Colborn KL, Knupp KG. Duration of use of oral cannabis extract in a cohort of pediatric epilepsy patients. *Epilepsia.* (2017) 58:123–7. doi: 10.1111/epi.13617
48. Slomski A. Fewer seizures with cannabidiol in catastrophic epilepsy. *JAMA.* (2017) 318:323. doi: 10.1001/jama.2017.8846
49. Rosenberg EC, Louik J, Conway E, Devinsky O, Friedman D. Quality of life in childhood epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol. *Epilepsia.* (2017) 58:e96–100. doi: 10.1111/epi.13815
50. Ridler C. Epilepsy: Cannabidiol reduces seizure frequency in Dravet syndrome. *Nat Rev Neurol.* (2017) 13:383. doi: 10.1038/nrneuro.2017.86

51. O'Connell BK, Gloss D, Devinsky O. Cannabinoids in treatment-resistant epilepsy: a review. *Epilepsy Behav.* (2017) 70(Pt B):341–8. doi: 10.1016/j.yebeh.2016.11.012
52. Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, et al. Trial of cannabidiol for drug-resistant seizures in the dravet syndrome. *N Engl J Med.* (2017) 376:2011–20. doi: 10.1056/NEJMoa1611618
53. Aguirre-Velazquez CG. Report from a survey of parents regarding the use of cannabidiol (medicinal cannabis) in Mexican children with refractory epilepsy. *Neurol Res Int.* (2017) 2017:2985729. doi: 10.1155/2017/2985729
54. Tzadok M, Uliel-Siboni S, Linder I, Kramer U, Epstein O, Menascu S, et al. CBD-enriched medical cannabis for intractable pediatric epilepsy: the current Israeli experience. *Seizure.* (2016) 35:41–44. doi: 10.1016/j.seizure.2016.01.004
55. Rosemergy I, Adler J, Psirides A. Cannabidiol oil in the treatment of super refractory status epilepticus. A case report. *Seizure.* (2016) 35:56–8. doi: 10.1016/j.seizure.2016.01.009
56. Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. *Lancet Neurol.* (2016) 15:270–8. doi: 10.1016/S1474-4422(15)00379-8
57. Press CA, Knupp KG, Chapman KE. Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. *Epilepsy Behav.* (2015) 45:49–52. doi: 10.1016/j.yebeh.2015.02.043
58. Hussain SA, Zhou R, Jacobson C, Weng J, Cheng E, Lay J, et al. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: a potential role for infantile spasms and Lennox-Gastaut syndrome. *Epilepsy Behav.* (2015) 47:138–41. doi: 10.1016/j.yebeh.2015.04.009
59. Cilio MR, Thiele EA, Devinsky O. The case for assessing cannabidiol in epilepsy. *Epilepsia.* (2014) 55:787–90. doi: 10.1111/epi.12635
60. Porter BE, Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. *Epilepsy Behav.* (2013) 29:574–7. doi: 10.1016/j.yebeh.2013.08.037
61. Siniscalco D, Sapone A, Giordano C, Cirillo A, de Magistris L, Rossi F, et al. Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders. *J Autism Dev Disord.* (2013) 43:2686–95. doi: 10.1007/s10803-013-1824-9
62. Karhson DS, Krasinska KM, Dallaire JA, Libove RA, Phillips JM, Chien AS, et al. Plasma anandamide concentrations are lower in children with autism spectrum disorder. *Mol Autism.* (2018) 9:18. doi: 10.1186/s13229-018-0203-y
63. Busquets-García A, Gomis-Gonzalez M, Guegan T, Agustin-Pavon C, Pastor A, Mato S, et al. Targeting the endocannabinoid system in the treatment of fragile X syndrome. *Nat Med.* (2013) 19:603–7. doi: 10.1038/nm.3127
64. Cao X, Tabuchi K. Functions of synapse adhesion molecules neurexin/neuroligins and neurodevelopmental disorders. *Neurosci Res.* (2017) 1163–9. doi: 10.1016/j.neures.2016.09.005
65. Jung KM, Sepers M, Henstridge CM, Lassalle O, Neuhofer D, Martin H, et al. Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. *Nat Commun.* (2012) 3:1080. doi: 10.1038/ncomms2045
66. Kerr DM, Downey L, Conboy M, Finn DP, Roche M. Alterations in the endocannabinoid system in the rat valproic acid model of autism. *Behav Brain Res.* (2013) 249:124–32. doi: 10.1016/j.bbr.2013.04.043
67. Qin M, Zeidler Z, Moulton K, Krych L, Xia Z, Smith CB. Endocannabinoid-mediated improvement on a test of aversive memory in a mouse model of fragile X syndrome. *Behav Brain Res.* (2015) 291:164–71. doi: 10.1016/j.bbr.2015.05.003
68. Malcher-Lopes R. Cannabinoids help to unravel etiological aspects in common and bring hope for the treatment of autism and epilepsy. *Rev Biol.* (2014) 13:43–59. doi: 10.7594/revbio.13.01.07
69. Chez MG, Chang M, Krasne V, Coughlan C, Kominsky M, Schwartz A. Frequency of epileptiform EEG abnormalities in a sequential screening of autistic patients with no known clinical epilepsy from 1996 to 2005. *Epilepsy Behav.* (2006) 8:267–71. doi: 10.1016/j.yebeh.2005.11.001
70. Markram K, Markram H. The intense world theory - a unifying theory of the neurobiology of autism. *Front Hum Neurosci.* (2010) 4:224. doi: 10.3389/fnhum.2010.00224
71. Shannon S, Opila-Lehman J. Effectiveness of cannabidiol oil for pediatric anxiety and insomnia as part of posttraumatic stress disorder: a case report. *Perm J.* (2016) 20:108–111. doi: 10.7812/TPP/16-005
72. Blessing EM, Steenkamp MM, Manzanera J, Marmar CR. Cannabidiol as a potential treatment for anxiety disorders. *Neurotherapeutics.* (2015) 12:825–36. doi: 10.1007/s13311-015-0387-1
73. Bergamaschi MM, Queiroz RH, Chagas MH, de Oliveira DC, De Martinis BS, Kapczinski F, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. *Neuropsychopharmacology.* (2011) 36:1219–26. doi: 10.1038/npp.2011.6
74. Zuardi AW, Cosme RA, Graeff FG, Guimaraes FS. Effects of ipsapirone and cannabidiol on human experimental anxiety. *J Psychopharmacol.* (1993) 7(1 Suppl):82–8. doi: 10.1177/026988119300700112
75. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. *Psychopharmacology.* (1982) 76:245–50. doi: 10.1007/BF00432554
76. Zuardi AW, Morais SL, Guimaraes FS, Mechoulam R. Antipsychotic effect of cannabidiol. *J Clin Psychiatry.* (1995) 56:485–6.
77. Zuardi AW, Crippa JA, Hallak JE, Bhattacharyya S, Atakan Z, Martin-Santos R, et al. A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. *Curr Pharm Des.* (2012) 18:5131–40. doi: 10.2174/138161212802884681
78. Iseger TA, Bossong MG. A systematic review of the antipsychotic properties of cannabidiol in humans. *Schizophr Res.* (2015) 162:153–61. doi: 10.1016/j.schres.2015.01.033
79. Seeman P. Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose. *Transl Psychiatry.* (2016) 6:e920. doi: 10.1038/tp.2016.195
80. Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. *Transl Psychiatry.* (2012) 2:e94. doi: 10.1038/tp.2012.15
81. Kerr DM, Gilmartin A, Roche M. Pharmacological inhibition of fatty acid amide hydrolase attenuates social behavioural deficits in male rats prenatally exposed to valproic acid. *Pharmacol Res.* (2016) 113(Pt A):228–35. doi: 10.1016/j.phrs.2016.08.033
82. Lorenz R. On the application of cannabis in paediatrics and epileptology. *Neuro Endocrinol Lett.* (2004) 25:40–4.
83. Jones RM, Carberry C, Hamo A, Lord C. Placebo-like response in absence of treatment in children with Autism. *Autism Res.* (2017) 10:1567–72. doi: 10.1002/aur.1798

Conflict of Interest: PF-T was employed by ePrimeCare Healthcare SA, Belo Horizonte, Brazil. RM-L has provided technical advisement to Grüne Labs, Pando, Uruguay.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Fleury-Teixeira, Caixeta, Ramires da Silva, Brasil-Neto and Malcher-Lopes. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.